Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Атмосфера. Новости кардиологии
2022 / N 1

Антикоагулянтная терапия в условиях особых рисков тромбозов и кровотечений у онкологических больных
Е.И. Емелина, Г.Е. Гендлин, И.Г. Никитин

References

1. Our World in Data. Roser M, Ritchie H. Cancer. Available from: https://ourworldindata.org/cancer Accessed 2022 Jul 19.
2. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GYH, Lyon AR, Lopez Fernandez T, Mohty D, Piepoli MF, Tamargo J, Torbicki A, Suter TM; ESC Scientific Document Group. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). European Heart Journal 2016 Sep;37(36):2768-801.
3. Vasyuk YuA, Gendlin GE, Yemelina EI, Shupenina EYu, Balluzek MF, Barinova IV, Vitsenya MV, Davydkin IL, Dundua DP, Duplyakov DV, Zateyshchikov DA, Zolotovskaya IA, Konradi AO, Lopatin YuM, Moiseyeva OM, Nedogoda SV, Nedoshivin AO, Nikitin IG, Poltavskaya MG, Potiyevskaya VI, Repin AN, Sumin AN, Zotova LA, Tumyan GS, Shlyakhto EV, Khatkov IE, Yakushin SS, Belenkov YuN. Consensus statement of Russian experts on the prevention, diagnosis and treatment of cardiotoxicity of anticancer therapy. Russian Journal of Cardiology 2021;26(9):152-233 (In Russian).
4. Sushinskaya TV, Stuklov NI, Dobrokhotova YuE. Hemostasis and cancer-associated thrombosis: modern prevention and treatment. PA Herzen Journal of Oncology 2018;7(4):64-72 (In Russian).
5. Lateef N, Kapoora V, Ahsan MJ, Latif A, Ahmed U, Mirza M, Anwar F, Holmberg M. Atrial fibrillation and cancer; understanding the mysterious relationship through a systematic review. Journal of Community Hospital Internal Medicine Perspectives 2020 May;10(2):127-32.
6. D’Souza M, Carlson N, Fosbøl E, Lamberts M, Smedegaard L, Nielsen D, Torp-Pedersen C, Gislason G, Schou M. CHA2DS2-VASc score and risk of thromboembolism and bleeding in patients with atrial fibrillation and recent cancer. European Journal of Preventive Cardiology 2018 Apr;25(6):651-8.
7. Bungo B, Chaudhury P, Arustamyan M. Rikhi R, Hussain M, Collier P, Kanj M, Khorana AA, Mentias A, Moudgil R. Better prediction of stroke in atrial fibrillation with incorporation of cancer in CHA2DS2VASC score: CCHA2DS2VASC score. International Journal of Cardiology. Heart & Vasculature 2022 Jun;41:101072.
8. López-Fernández T, Martín-García A, Roldán Rabadán I, Mitroi C, Mazón Ramos P, Díez-Villanueva P, Escobar Cervantes C, Alonso Martín C, Alonso Salinas GL, Arenas M, Arrarte Esteban VI, Ayala de La Peña F, Castro Fernández A, García Pardo H, García-Sanz R, González Porras JR, López de Sá E, Lozano T, Marco Vera P, Martínez Marín V, Mesa Rubio D, Montero Á, Oristrell G, Pérez de Prado A, Velasco Del Castillo S, Virizuela Echaburu JA, Zatarain-Nicolás E, Anguita Sánchez M, Tamargo Menéndez J; Expert reviewers. Atrial fibrillation in active cancer patients: expert position paper and recommendations. Revista Española de Cardiología 2019 Sep;72(9):749-59.
9. Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A, Tocchetti CG, Moslehi JJ, Groarke JD, Bergler-Klein J, Khoo V, Tan LL, Anker MS, von Haehling S, Maack C, Pudil R, Barac A, Thavendiranathan P, Ky B, Neilan TG, Belenkov Y, Rosen SD, Iakobishvili Z, Sverdlov AL, Hajjar LA, Macedo AVS, Manisty C, Ciardiello F, Farmakis D, de Boer RA, Skouri H, Suter TM, Cardinale D, Witteles RM, Fradley MG, Herrmann J, Cornell RF, Wechelaker A, Mauro MJ, Milojkovic D, de Lavallade H, Ruschitzka F, Coats AJS, Seferovic PM, Chioncel O, Thum T, Bauersachs J, Andres MS, Wright DJ, López-Fernández T, Plummer C, Lenihan D. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. European Journal of Heart Failure 2020 Nov;22(11):1945-60.
10. Mosarla RC, Vaduganathan M, Qamar A, Moslehi J, Piazza G, Giugliano RP. Anticoagulation strategies in patients with cancer: JACC review topic of the week. Journal of the American College of Cardiology 2019 Mar;73(11):1336-49.
11. Fernandes CJ, Morinaga LTK, Alves JL Jr, Castro MA, Calderaro D, Jardim CVP, Souza R. Cancer-associated thrombosis: the when, how and why. European Respiratory Review 2019 Mar;28(151):180119.
12. Grover SP, Hisada YM, Kasthuri RS, Reeves BN, Mackman N. Cancer therapy-associated thrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology 2021 Apr;41(4):1291-305.
13. Lee AY, Peterson EA. Treatment of cancer-associated thrombosis. Blood 2013 Oct;122(14):2310-7.
14. Halvorsen S, Atar D, Yang H, De Caterina R, Erol C, Garcia D, Granger CB, Hanna M, Held C, Husted S, Hylek EM, Jansky P, Lopes RD, Ruzyllo W, Thomas L, Wallentin L. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. European Heart Journal 2014 Jul;35(28):1864-72.
15. Melloni С, Dunning А, Granger СВ, Thomas L, Khouri MG, Garcia DA, Hylek EM, Hanna M, Wallentin L, Gersh BJ, Douglas PS, Alexander JH, Lopes RD. Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and a history of cancer: insights from the ARISTOTLE trial. The American Journal of Medicine 2017 Dec;130(12):1440-8.e1.
16. Shah S, Norby FL, Datta YH, Lutsey PL, MacLehose RF, Chen LY, Alonso A. Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation. Blood Advances 2018 Feb;2(3):200-9.
17. Ording AG, Horváth-Puhó E, Adelborg K, Pedersen L, Prandoni P, Sørensen HT. Thromboembolic and bleeding complications during oral anticoagulation therapy in cancer patients with atrial fibrillation: a Danish nationwide population-based cohort study. Cancer Medicine 2017 Jun;6(6):1165-72.
18. Peixoto de Miranda ÉJF, Takahashi T, Iwamoto F, Yamashiro S, Samano E, Macedo AVS, Ramacciotti E. Drug-drug interactions of 257 antineoplastic and supportive care agents with 7 anticoagulants: a comprehensive review of interactions and mechanisms. Clinical and Applied Thrombosis/Hemostasis 2020 Jan-Dec;26:1076029620936325.
19. Agnelli G, Becattini C, Meyer G, Muñoz A, Huisman MV, Connors JM, Cohen A, Bauersachs R, Brenner B, Torbicki A, Sueiro MR, Lambert C, Gussoni G, Campanini M, Fontanella A, Vescovo G, Verso M; Caravaggio Investigators. Apixaban for the treatment of venous thromboembolism associated with cancer. The New England Journal of Medicine 2020 Apr 23;382(17):1599-607.
20. Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, Huisman MV, Humbert M, Jennings CS, Jiménez D, Kucher N, Lang IM, Lankeit M, Lorusso R, Mazzolai L, Meneveau N, Ní Áinle F, Prandoni P, Pruszczyk P, Righini M, Torbicki A, Van Belle E, Zamorano JL; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). European Heart Journal 2020 Jan;41(4):543-603.
21. Streiff MB, Abutalib SA, Farge D, Murphy M, Connors JM, Piazza G. Update on guidelines for the management of cancer-associated thrombosis. The Oncologist 2021 Jan;26(1):e24-40.
22. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. The New England Journal of Medicine 2013 Aug;369(9):799­808.
23. Shaw JR, Douketis J, Le Gal G, Carrier M. Periprocedural interruption of anticoagulation in patients with cancer-associated venous thromboembolism: an analysis of thrombotic and bleeding outcomes. Journal of Thrombosis and Haemostasis 2019 Jul;17(7):1171-8.
24. Agnelli G, Becattini C, Bauersachs R, Brenner B, Campanini M, Cohen A, Connors JM, Fontanella A, Gussoni G, Huisman MV, Lambert C, Meyer G, Muñoz A, Abreu de Sousa J, Torbicki A, Verso M, Vescovo G; Caravaggio Study Investigators. Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio Study. Thrombosis and Haemostasis 2018 Sep;1189(9):1668­78.
25. Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A, Kuruvilla P, Hill D, Spadafora S, Marquis K, Trinkaus M, Tomiak A, Lee AYY, Gross PL, Lazo-Langner A, El-Maraghi R, Goss G, Le Gal G, Stewart D, Ramsay T, Rodger M, Witham D, Wells PS; AVERT Investigators. Apixaban to prevent venous thromboembolism in patients with cancer. The New England Journal of Medicine 2019 Feb;380(8):711-9.
26. Angelini DE, Radivoyevitch T, McCrae KR, Khorana AA. Bleeding incidence and risk factors among cancer patients treated with anticoagulation. American Journal of Hematology 2019 Jul;94(7):780-5.
27. Becattini C, Bauersachs R, Maraziti G, Bertoletti L, Cohen A, Jonnors JM, Manfellotto D, Sanchez A, Brenner B, Agnelli G. Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. Haematologica 2022 Jul;107(7):1567-76.
28. Verso M, Munoz A, Bauersachs R, Huisman MV, Mandalà M, Vescovo G, Becattini C, Agnelli G. Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism. European Journal of Cancer (Oxford, England: 1990) 2021 May;148:371-81.
29. Giustozzi M, Connors JM, Ruperez Blanco AB, Szmit S, Falvo N, Cohen AT, Huisman M, Bauersachs R, Dentali F, Becattini C, Agnelli G. Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: Insights from the Caravaggio study. Journal of Thrombosis and Haemostasis 2021 Nov;19(11):2751-9.
  

[ Содержание выпуска N 1 | Выпуски журнала | Список журналов ]